GSK Plc is a long-term underperformer among Europe’s Big Pharma stocks. And with key drug patents set to expire and vaccine ...

GSK’s share price has fallen a long way on a combination of factors, but do its recent strong results leave its current price ...

After years of limping along, the GSK share price has leapt 11% in one month. But one of America's richest investors is ...

UK pharma major GSK late Friday announced that the US Food and Drug Administration (FDA) has approved Penmenvy (meningococcal ...

Ken Griffin's Citadel hedge fund places £305M short bet against GSK, with skepticism over long-term pipeline and recent stock ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

The UK's major stock indexes have declined for the third consecutive session, influenced by mixed corporate earnings and ...

Citadel revealed it has taken a £305m short position against GSK. This rises in value as the share price falls. This is the biggest bet against this business since 2013. Under UK rules ...

LONDON: The main UK stock indexes fell for a third straight session on Thursday, trading near two-week lows, as heavyweight ...